Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392865 | 1.00 | DGAT1 (0.55) | DGAT1SOAT1 | |
| SCHEMBL13223421 | 0.92 | DGAT1 (0.54) | DGAT1SOAT1 | |
| SCHEMBL1424776 | 0.86 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL1424773 | 0.86 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL3648352 | 0.86 | DGAT1 (0.55) | DGAT1 | |
| SCHEMBL3648349 | 0.86 | DGAT1 (0.55) | DGAT1 | |
| SCHEMBL16985190 | 0.85 | DGAT1 (0.49) | DGAT1 | |
| SCHEMBL3643002 | 0.85 | DGAT1 (0.40) | DGAT1SOAT1 | |
| SCHEMBL3397610 | 0.85 | DGAT1 (0.40) | DGAT1SOAT1 | |
| SCHEMBL3643006 | 0.85 | DGAT1 (0.40) | DGAT1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
| EP-2185567-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016462-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | DGAT1, DGAT2, MOGAT2 | DGAT1 1/4885SOAT1 11/4885 |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CXCR2 | DGAT1 4238/4885SOAT1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.